FINANCIAL INFORMATION

and liabilities of US$14.1 million. Our net non-cash charges during the year ended December 31, 2016
primarily consisted of US$1.9 million of depreciation expense, US$10.6 million of share-based
compensation expense, a US$1.4 million loss on sale of available-for-sale securities and a US$1.5
million loss from changes in the fair value of financial instruments related to the valuation changes
of warrants and option liabilities that were exercised during the year.

Investing Activities

Net cash used in investing activities was US$394.4 million for the three months ended March 31,
2018, which consisted of purchases of investment securities of US$632.2 million, a purchase of
US$10.0 million of in-process research and development related to the license agreement with Mirati
and capital expenditures of US$9.7 million primarily related to our Guangzhou and Suzhou
manufacturing facilities, partially offset by sales and maturities of investment securities of US$257.6
million.

Net cash provided by investing activities was US$43.5 million for the three months ended March
31, 2017, which consisted of sales and maturities of investment securities of US$65.6 million,
partially offset by purchases of investment securities of US$14.7 million, capital expenditures of
US$5.1 million and a US$2.3 million payment related to the Guangzhou land auction deposit.

Net cash used in investing activities was US$356.3 million for the year ended December 31,
2017, which was primarily due to the purchase of investment securities of US$741.3 million, capital
expenditures of US$46.4 million primarily related to our Guangzhou and Suzhou manufacturing
facilities and US$12.4 million paid to acquire land use rights in Guangzhou, China, partially offset by
US$423.8 million of proceeds from sale or maturity of investment securities and US$19.9 million of
cash acquired in the acquisition of BeiGene Pharmaceutical (Shanghai), net of cash paid.

Net cash used in investing activities was US$221.8 million for the year ended December 31,
2016, which was primarily due to the purchase of investment securities of US$382.1 million and
capital expenditures of US$23.5 million, partially offset by US$183.7 million of proceeds from sales
of investment securities.

Financing Activities

Net cash provided by financing activities was US$763.9 million for the three months ended
March 31, 2018, which consisted of US$758.0 million of proceeds, net of underwriter discounts, from
our follow-on public offering of ADSs and US$6.3 million from the exercise of employee stock
options, offset by the payment of US$0.4 million of follow-on public offering costs.

Net cash provided by financing activities was US$2.5 million for the three months ended March

31, 2017, which related to proceeds from a short-term loan to BeiGene Biologics from GET.

Net cash provided by financing activities was US$490.4 million for the year ended December 31,
2017, which was primarily due to US$188.5 million of net proceeds from our follow-on public
offering, net of underwriters’ discounts and offering costs, US$149.9 million in proceeds from the
sales of our ordinary shares to Celgene Switzerland, net of costs, US$132.8 million of proceeds from

— 287 —

